Romanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Psychological Concomitants of Morquio Syndrome (The MAP Study)

Numai utilizatorii înregistrați pot traduce articole
Log In / Înregistrare
Linkul este salvat în clipboard
stareEfectuat
Sponsorii
Nadia Ali, PhD
Colaboratori
BioMarin Pharmaceutical

Cuvinte cheie

Abstract

Mucopolysaccharidosis IV, also known as MPS IV or Morquio disease, is a rare autosomal recessive genetic lysosomal storage disorder. Research thus far regarding lysosomal storage diseases (LSDs) in general, including Morquio, has primarily focused on exploring the causes of and finding a treatment for the physical aspects of the various diseases. Less attention has been paid to the psychological or emotional toll of these diseases, whether they are direct symptoms of the diseases themselves or reactions to living with a chronic progressive disease.
It is well established in the health psychology literature, however, that the interaction between our physical health and our psychological health is bidirectional; that is, just as our physical health affects us emotionally (e.g. chronic pain can contribute to depression), so can our psychological health affect us physically (e.g. anxiety can contribute to feelings of chest pain). It is thus critically important to pay attention to the emotional and psychological symptoms associated with all lysosomal storage diseases, including Morquio, and expand our treatment standard of care to include mental health treatment, if necessary.
The first step in understanding and treating psychological conditions in Morquio disease is determining the natural occurrence of psychological symptoms in this population in comparison with non-medical populations. As little has been done in this regard, a pilot study documenting the occurrence rate of psychological issues and overall quality of life in patients with Morquio is the first item in order and will be the focus of this study.
Approximately 20 patients with Morquio disease will be invited to participate, recruited through Emory's Lysosomal Storage Disease Center, as well as through attendance at Morquio support groups and relevant regional, national and/or international meetings. Once consented, patients will be asked to complete three different self-report questionnaires, including the Achenbach System of Empirically Based Assessment (ASEBA) Adult Self-Report (ASR) or Older Adult Self-Report (OASR) questionnaire, the Short Form 36-item Health Questionnaire (SF-36), and the Brief Pain Inventory (BPI). Group aggregate data only will be reported; individual questionnaire content and results will be held confidential, except as in accordance with Georgia law relating to reporting of child or elder abuse, suicidal and/or homicidal intent. Completion of these questionnaires will complete subjects' participation in this pilot study.

Datele

Ultima verificare: 11/30/2013
Primul depus: 12/12/2012
Inscriere estimată trimisă: 12/17/2012
Prima postare: 12/18/2012
Ultima actualizare trimisă: 12/01/2013
Ultima actualizare postată: 12/03/2013
Data actuală de începere a studiului: 06/30/2012
Data estimată de finalizare primară: 09/30/2013
Data estimată de finalizare a studiului: 09/30/2013

Stare sau boală

Morquio Disease
Mucopolysaccharidosis IV

Fază

-

Criterii de eligibilitate

Vârste eligibile pentru studiu 18 Years La 18 Years
Sexe eligibile pentru studiuAll
Metoda de eșantionareNon-Probability Sample
Acceptă voluntari sănătoșida
Criterii

Inclusion Criteria:

1. Documented clinical diagnosis of MPS IV based on clinical signs and symptoms of MPS IV and documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis of MPS IV.

2. Patient is at least 18 years old.

3. Patient is not currently receiving enzyme replacement therapy for MPS IV.

4. Patient must provide written, informed consent prior to study participation.

Exclusion Criteria:

1. Previous treatment with ERT

2. Previous hematopoietic stem-cell transplant

3. Patient has a clinically significant disease (with the exception of symptoms of Morquio), including clinically significant immunologic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstances that, in the opinion of the investigator, would confound the effects of Morquio upon study variables

Rezultat

Măsuri de rezultate primare

1. ASEBA Self-Report [At enrollment, as a single-timepoint only]

Self-report questionnaire assessing psychological and adaptive functioning well-being

Măsuri de rezultate secundare

1. Brief Pain Inventory [At enrollment, as a single-timepoint only]

Self-report measure of subjective pain levels and interference of pain in daily functioning

2. SF-36 [At enrollment, as a single-timepoint only]

Brief self-report measure of quality of life

Alăturați-vă paginii
noastre de facebook

Cea mai completă bază de date cu plante medicinale susținută de știință

  • Funcționează în 55 de limbi
  • Cure pe bază de plante susținute de știință
  • Recunoașterea ierburilor după imagine
  • Harta GPS interactivă - etichetați ierburile în locație (în curând)
  • Citiți publicațiile științifice legate de căutarea dvs.
  • Căutați plante medicinale după efectele lor
  • Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate

Google Play badgeApp Store badge